Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04869098
Other study ID # H-2020-131
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 27, 2021
Est. completion date July 31, 2024

Study information

Verified date March 2023
Source University of Adelaide
Contact Amy Hutchison, PhD
Phone 8128 4862
Email amy.hutchison@adelaide.edu.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare the effects of a whey protein supplement or a placebo consumed before the evening meal on health outcomes in night shift workers.


Description:

Participants are assigned in random order to two conditions, for 12 days each. The interventions are 1) a 30g whey protein preload consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given. 2) an identical mixed-nutrient drink matched for caloric content, taste and palatability consumed 1-1.5 hr prior to their main evening meal every day for 12 days(placebo). Conditions are separated by a 2-week washout period, during which participants will be encouraged to maintain their habitual diet and physical activity levels. Metabolic testing will be performed at baseline, and at the end of both conditions.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria: - Female - Night shift workers (with a minimum of 6 months in their current shift work schedule) - 35-65 years - BMI 28.0-35.0 kg/m2; waist circumference > 80cm - Weight stable in the past 6 months Exclusion Criteria: - Those working standard day time hours only, or those who work less than three to four night shifts per fortnight on average - Personal history and/or diagnosis of: diabetes, cancer, major psychiatric disorders, liver disease, gastro-intestinal surgery or disease (including malabsorption), eating disorders, anaemia, insomnia or cardiovascular disease, and/or any other condition deemed unstable by the study physician - Taking medications known to alter body composition or metabolism, including (but not limited to): any medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, Glucagon-like peptide-1 (GLP-1) analogues [i.e. exenatide], thiazolidinediones or DPP-IV inhibitors [i.e. 'gliptins']), medications affecting weight, appetite or gut motility (i.e. diuretics, domperidone, cisapride, orlistat, phentermine, topiramate) - Participants who are taking stable doses (i.e. > 12 months) of androgenic medications (i.e. testosterone) or SSRI's will not be excluded. Personal history/diagnosis (self-reported) of diabetes (type 1 or 2), major psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, eating disorders), gastrointestinal disorders, haematological disorders (i.e. thalassemia, iron-deficiency anaemia) insomnia, or any other medical condition, deemed unstable by the study physician - Pregnant, planning a pregnancy or breastfeeding - Those who have lost or gained >5% of body weight in the last 6 months - Those who consume four or more standard drinks on a single occasion at a 'daily or almost daily' occurrence - current smokers of cigarettes/marijuana/e-cigarettes/vaporisers - unable to comprehend the study protocol (i.e. due to English language or cognitive difficulties)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
whey protein
Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
Placebo
Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.

Locations

Country Name City State
Australia University of Adelaide Adelaide South Australia

Sponsors (1)

Lead Sponsor Collaborator
University of Adelaide

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycaemic response Change in glucose (AUC) following a standard breakfast 12 days (3 hours meal test)
Secondary 24-hour glucose profiles Change in 24-hour glucose profiles assessed by continuous glucose monitoring 12 days
Secondary Glucose variability Change in 24-hour glucose variability (as SD, standard deviation) assessed by continuous glucose monitoring 12 days
Secondary Glucose variability Change in 24-hour glucose variability (as CV, coefficients of variation) assessed by continuous glucose monitoring 12 days
Secondary Glucose variability Change in 24-hour glucose variability (as MAGE, mean amplitude of gylcaemic excursions) assessed by continuous glucose monitoring 12 days
Secondary GLP-1 Change in GLP-1 (AUC) following a standard breakfast 12 days (3 hours meal test)
Secondary GIP Change in GIP (AUC) following a standard breakfast 12 days (3 hours meal test)
Secondary glucagon Change in glucagon (AUC) following a standard breakfast 12 days (3 hours meal test)
Secondary Insulin Change in fasting and postprandial insulin following a standard breakfast 12 days
Secondary Ghrelin Change in ghrelin (AUC) following a standard breakfast 12 days (3 hours meal test)
Secondary PYY Change in YY (AUC) following a standard breakfast 12 days
Secondary Adiponectin Change in fasting adiponectin 12 days
Secondary C-Reactive Protein (CRP) Change in fasting CRP 12 days
Secondary Blood lipids Changes in blood lipid profile (total cholesterol, HDL-, LDL-cholesterol and triglycerides) 12 days
Secondary Blood pressure Changes in systolic blood pressure and diastolic blood pressure 12 days
Secondary Resting metabolic rate Changes in resting metabolic rate 12 days
Secondary respiratory quotient Changes in respiratory quotient 12 days
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A